Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.83 [0.69, 1.00] | | < 1 | | 0% | 1 study (1/-) | 97.5 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.82 [0.70, 0.96] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | important | - |
CRR | 1.96 [1.21, 3.17] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
DOR | 0.70 [0.46, 1.08] | | < 1 | | 0% | 1 study (1/-) | 94.7 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.15 [0.88, 1.51] | | > 1 | | 0% | 1 study (1/-) | 84.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 2.34 [0.43, 12.83] | | < 1 | | 0% | 1 study (1/-) | 16.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.92 [0.63, 1.34] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.27 [0.70, 2.27] | | < 1 | | 0% | 1 study (1/-) | 21.6 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.05 [0.79, 1.40] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.11 [0.85, 1.46] | | < 1 | | 0% | 1 study (1/-) | 21.9 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.33 [0.99, 1.80] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.04 [0.53, 2.03] | | < 1 | | 0% | 1 study (1/-) | 45.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.02 [0.72, 1.43] | | < 1 | | 0% | 1 study (1/-) | 46.4 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.96 [0.60, 6.40] | | < 1 | | 0% | 1 study (1/-) | 13.4 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Anaemia TRAE (grade 3-4) | 1.11 [0.67, 1.84] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 2.00 [0.82, 4.92] | | < 1 | | 0% | 1 study (1/-) | 6.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.59 [0.27, 25.03] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 2.61 [0.70, 9.73] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.73 [0.31, 9.49] | | < 1 | | 0% | 1 study (1/-) | 26.5 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 2.01 [1.12, 3.62] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.72 [0.06, 51.51] | | < 1 | | 0% | 1 study (1/-) | 37.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.86 [0.02, 43.49] | | < 1 | | 0% | 1 study (1/-) | 52.9 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.11 [0.55, 2.26] | | < 1 | | 0% | 1 study (1/-) | 38.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Anaemia AE (grade 3-4) | 1.08 [0.82, 1.42] | | < 1 | | 0% | 1 study (1/-) | 29.8 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 1.43 [0.81, 2.50] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.66 [0.37, 1.17] | | < 1 | | 0% | 1 study (1/-) | 92.1 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 1.76 [0.81, 3.80] | | < 1 | | 0% | 1 study (1/-) | 7.7 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 2.22 [1.05, 4.68] | | < 1 | | 0% | 1 study (1/-) | 1.8 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.74 [0.44, 1.24] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.54 [0.23, 1.27] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 1.38 [1.03, 1.84] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 1.25 [0.89, 1.76] | | < 1 | | 0% | 1 study (1/-) | 10.1 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.86 [0.37, 2.00] | | < 1 | | 0% | 1 study (1/-) | 63.9 % | NA | not evaluable | | non important | - |